Breaking News Instant updates and real-time market news.

CME

CME Group

$150.79

1.25 (0.84%)

, CBOE

CBOE Holdings

$124.25

0.82 (0.66%)

16:15
12/01/17
12/01
16:15
12/01/17
16:15

On The Fly: Top stock stories for Friday

The major averages were mixed and hugging the flat line in the early morning but quickly dropped when news broke that former National Security Advisor Michael Flynn would plead guilty to lying during the FBI probe and was willing to testify against President Trump. The news put the tax reform vote on the back burner, but when Senate leaders confirmed they had enough votes for its passage the market began to pare its losses. The market limped into the close but ended the week with gains and the averages remain close to all-time highs. ECONOMIC EVENTS: In the U.S., Markit's manufacturing PMI fell 0.7 points to 53.9 in the final print for November. This compares to 53.8 in the preliminary reading and 54.6 in October. The ISM manufacturing index dipped 0.5 points to 58.2 in November from 58.7 in October. Construction spending jumped 1.4% in October, marking a third straight monthly increase. In Asia, China's Caixin manufacturing PMI for November came in at 50.8, roughly in-line with expectations. In Europe, the final Eurozone manufacturing PMI for rose a tick to 60.1 from the 60 flash reading for November. Meanwhile, in Capitol Hill news, U.S. Senate Majority Leader Mitch McConnell said that the Republicans have the votes necessary to pass their tax bill, which they plan to do later in the day. In other news, Michael Flynn, President Trump's former National Security Adviser, pleaded guilty on Friday to lying to the FBI about discussions with Russian ambassador Sergey Kislyak last December. Flynn's conversations with Kislyak about foreign policy were part of a coordinated effort by aides running Trump's transition into the White House, according to documents released as part of Flynn's plea agreement. According to the New York Times, federal prosecutors say that Flynn was directed by a "very senior member" of the president's transition team in at least one instance. ABC News, citing people familiar with the plea agreement, reports that Flynn feels President Trump "has abandoned him and has agreed to answer questions about the president or anyone else." COMPANY NEWS: The Commodity Futures Trading Commission noted that the CME Group (CME) and the CBOE Futures Exchange (CBOE) self-certified new contracts for bitcoin futures products, and the Cantor Exchange self-certified a new contract for bitcoin binary options. CME Group announced that the initial listing of its Bitcoin futures contract will launch Monday, December 18, while CBOE said its impending launch date of Cboe bitcoin futures will be announced shortly... Meanwhile, car makers reported U.S. sales for the month of November today, with Ford (F) and Fiat Chrysler (FCAU) reporting year-over-year sales increases of 6.7% and 4%, respectively, while rival General Motors (GM) reported a 3% decline for the month. MAJOR MOVERS: Among the notable gainers following their earnings reports were Ambarella (AMBA), which jumped over 14%, and Nutanix (NTNX), which rose almost 10%. Among the noteworthy losers following their earnings reports were Genesco (GCO), which fell 17.85%, and Ulta Beauty (ULTA), which dropped 4.1%. INDEXES: The Dow dipped 40.76, or 0.17%, to 24,231.59, the Nasdaq lost 26.39, or 0.38%, to 6,847.59, and the S&P 500 declined 5.36, or 0.2%, to 2,642.22.

CME

CME Group

$150.79

1.25 (0.84%)

CBOE

CBOE Holdings

$124.25

0.82 (0.66%)

F

Ford

$12.58

0.055 (0.44%)

FCAU

Fiat Chrysler

$17.09

-0.015 (-0.09%)

GM

General Motors

$42.79

-0.305 (-0.71%)

AMBA

Ambarella

$62.03

7.76 (14.30%)

NTNX

Nutanix

$36.06

3.26 (9.94%)

GCO

Genesco

$25.53

-5.575 (-17.93%)

ULTA

Ulta Beauty

$212.58

-9.13 (-4.12%)

BTC

Bitcoin

  • 01

    Dec

  • 01

    Dec

  • 04

    Dec

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

  • 09

    Jan

  • 16

    Jan

CME CME Group
$150.79

1.25 (0.84%)

08/16/17
DBAB
08/16/17
NO CHANGE
Target $135
DBAB
Buy
CME Group reiterated as top exchange pick at Deutsche Bank
Deutsche Bank analyst Brian Bedell reiterates CME Group as his top exchange pick after hosting investor meetings with management. The company's "multiple organic growth opportunities" make the stock much more than just a play on interest rates or macro volatility, Bedell tells investors in a research note. He keeps a Buy rating on CME with a $135 price target.
07/12/17
SBSH
07/12/17
DOWNGRADE
Target $16
SBSH
Sell
Virtu Financial downgraded to Sell from Neutral at Citi
Citi analyst Ben Herbert downgraded Virtu Financial (VIRT) to Sell and lowered his price target for the shares to $16 from $17 after taking over lead coverage from William Katz. The analyst has concerns over peak penetration, dividend pressure and the likely reduction of consensus estimates. He recommends a pair trade of long CME Group (CME), short Virtu.
07/12/17
SBSH
07/12/17
INITIATION
Target $140
SBSH
Buy
CME Group initiated with a Buy at Citi
Citi analyst Ben Herbert started CME Group with a Buy rating and $140 price target. "Deep" franchises in Energy, Fed Fund Futures and Treasury Futures and Options make CME the best positioned U.S. exchange, the analyst contends.
09/08/17
LEHM
09/08/17
INITIATION
Target $139
LEHM
Overweight
CME Group initiated with an Overweight at Barclays
Barclays analyst Jeremy Campbell started CME Group with an Overweight rating and $139 price target. The analyst initiated U.S. Brokers, Asset Managers & Exchanges with a Neutral industry view.
CBOE CBOE Holdings
$124.25

0.82 (0.66%)

09/08/17
LEHM
09/08/17
INITIATION
Target $105
LEHM
Equal Weight
CBOE Holdings initiated with an Equal Weight at Barclays
Barclays analyst Jeremy Campbell started CBOE Holdings with an Equal Weight rating and $105 price target. The analyst initiated U.S. Brokers, Asset Managers & Exchanges with a Neutral industry view.
10/16/17
RBCM
10/16/17
DOWNGRADE
RBCM
Sector Perform
CBOE Holdings downgraded to Sector Perform from Outperform at RBC Capital
10/16/17
RBCM
10/16/17
DOWNGRADE
Target $108
RBCM
Sector Perform
CBOE Holdings downgraded to Sector Perform at RBC Capital on limited upside
As previously noted, RBC Capital analyst Peter Lenardos downgraded CBOE Holdings to Sector Perform from Outperform but also raised his price target to $108 from $100. Lenardos says he remains impressed with sustained momentum in the company's high margin proprietary trading volume and anticipates a sector-wide multiple expansion, but the 45% year-to-date stock price appreciation captures its near-term upside.
10/05/17
WELS
10/05/17
NO CHANGE
Target $120
WELS
Outperform
CBOE Holdings price target raised to $120 from $106 at Wells Fargo
Wells Fargo raised its price target for CBOE Holdings to $120 from $106 on valuation. The analyst reiterates an Outperform rating on the shares.
F Ford
$12.58

0.055 (0.44%)

10/31/17
MSCO
10/31/17
NO CHANGE
Target $10
MSCO
Underweight
Ford bull case view raised despite 'significant headwinds' at Morgan Stanley
Morgan Stanley analyst Adam Jonas raised his 2017 EPS estimate for Ford to near the midpoint of the company's guidance following its Q3 report and slightly increased his price target on the stock to $10 from $9. While he keeps an Underweight rating on Ford, stating that the headwinds it faces are significant, he also sees the "scope for an equally significant response" and raised his bull case to $25 from $18 given a sum-of-the-parts analysis under which he values Ford's truck business, including the F-series and others, at nearly $20 per share, Ford Europe, S. America and Asia Pacific at "slightly less than zero" and "Ford Future" at $3B, or 74c per Ford share.
10/30/17
GSCO
10/30/17
DOWNGRADE
GSCO
Sell
Goldman sees 28% downside in GM, downgrades shares to Sell
Goldman Sachs analyst David Tamberrino downgraded General Motors (GM) to Sell from Neutral saying his price target of $32 offers 28% potential downside. The analyst continues to believe the North America auto cycle has peaked and he remains cautious on the sector. He sees "outsized downside" to shares of GM and expects a negative earnings inflection in 2018. Ford's (F) recently refreshed F-Series leaves GM vulnerable to share loss in 2018, Tamberrino tells investors in a research note. The analyst views Ford shares as more fairly valued. He keeps a Neutral rating on the name while upping his target for the shares to $13 from $10.
10/16/17
RBCM
10/16/17
DOWNGRADE
Target $13
RBCM
Sector Perform
Ford downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Joseph Spak downgraded Ford to Sector Perform from Outperform, saying he believes new CEO Jim Hackett has a solid long-term vision but it is very early in the turnaround and he thinks it will take time for change to come. Consensus 2018 numbers look high, said Spak, who keeps a $13 price target on Ford shares.
10/13/17
10/13/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ford (F) downgraded to Equal Weight from Overweight at Barclays with analyst Brian Johnson saying the company is starting "substantially behind" General Motors (GM) in current North America margins, and behind both GM and Tesla (TSLA) in its positioning for the "megatrends and disruptive mobility." 2. HP Enterprise (HPE) downgraded to Neutral from Buy at Citi with analyst Jim Suva saying fundamentals in the company's core enterprise group remain challenging, and accelerated restructuring payments will pressure core fee cash flow in fiscal year 2018. 3. XL Group (XL) downgraded to Sell from Hold at Deutsche Bank with analyst Joshua Shanker saying the company may be underestimating the impact of third quarter catastrophes, which creates downside risk to consensus estimates. 4. HubSpot (HUBS) downgraded to Sector Weight from Overweight at KeyBanc with analyst Brent Bracelin saying the risk/reward looks balanced with the shares up 82% year-to-date. 5. Hostess Brands (TWNK) downgraded to Sell from Neutral at UBS with analyst Steven Strycula saying slowing category trends, market share loss in its Sweet Baked Goods unit and recent management turnover create an unfavorable setup. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FCAU Fiat Chrysler
$17.09

-0.015 (-0.09%)

09/14/17
EVER
09/14/17
NO CHANGE
EVER
Outperform
Fiat Chrysler liklely to spinout certain businesses, says Evercore ISI
Evercore ISI analyst George Galliers said its high probability Fiat Chrysler spins-out or sells certain components businesses, most likely Magneti Marelli and Comau units. The analyst said CEO Marchonne has made comments that the components businesses do not belong and notes his history of unlocking shareholder value through M&A. Galliers expects actions before Marchonne's retirement at the end of 2018. The analyst rates shares an Outperform and increased his price target to EURO$17.00 from EURO$12.00.
09/18/17
MSCO
09/18/17
NO CHANGE
MSCO
Underweight
Ford's new leaders may be better positioned for Waymo deal, says Morgan Stanley
Morgan Stanley analyst Adam Jonas previewed Ford's (F) strategic update scheduled for October 3, calling it an important event that could have a potentially significant impact on the perception of the company's long-term direction. Noting prior media reports about talks between Ford and Google (GOOG) on autonomous cars that reportedly fell apart in 2016, Jonas opined that Ford's new leadership may be better positioned to potentially negotiate a partnership with Alphabet's autonomous car division Waymo, but he noted that the companies have not said whether they are currently considering a deal. Ford may not have the same type of brands as Fiat Chrysler (FCAU) that are conducive to potential carve-outs, but Jonas would not exclude the potential for it to conduct a review of its portfolio as part of its strategy to become a mobility company, he added.
11/10/17
11/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Buy from Hold at Needham with analyst Kevin Caliendo saying the stock's risk/reward is favorable, especially if CVS is able to consummate the reported merger with Aetna (AET). 2. Kohl's (KSS) upgraded to Outperform from Neutral at Baird with analyst Mark Altschwager saying Kohl's improving product portfolio and strong loyalty position the company for the holiday season, while cost savings and inventory reductions provide free-cash-flow visibility near-term. 3. Fiat Chrysler (FCAU) upgraded to Neutral from Sell at Citi. 4. Comcast (CMCSA) upgraded to Action List Buy from Buy at TD Securities. 5. Hyatt (H) upgraded to Buy from Hold at Berenberg with analyst Stuart Gordon saying the potential returns from the company's real estate disposals are being underappreciated. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/10/17
SBSH
11/10/17
UPGRADE
SBSH
Neutral
Fiat Chrysler upgraded to Neutral from Sell at Citi
Citi analyst Mike Tyndall upgraded Fiat Chrysler to Neutral and raised his price target for the shares to EUR 15.60 from EUR 11.30.
GM General Motors
$42.79

-0.305 (-0.71%)

11/28/17
MSCO
11/28/17
NO CHANGE
Target $43
MSCO
Equal Weight
GM may have hard time exceeding autonomous expectations, says Morgan Stanley
Ahead of General Motors' autonomous car events on November 29 and 30, Morgan Stanley analyst Adam Jonas said the company may find it difficult to top the rising expectations for its leadership in this "hotly contested" area. Investor sentiment around GM "vastly exceeds" where it was earlier this year, both because the company has executed and the global light vehicle market has held up better than expected, but also because the company has changed the narrative of the company's future to one where it can exert leadership in key areas such as shared mobility, connected and electric cars and autonomous vehicles, Jonas tells investors. He thinks GM will give a timeline for deploying fully autonomous fleets in a service within quarters, not years, but also believes its autonomous driving efforts are more likely to be a modest drag on earnings than a benefit for some years to come. Jonas keeps an Equal Weight rating and $43 price target on GM shares.
12/01/17
LEHM
12/01/17
NO CHANGE
Target $57
LEHM
Overweight
Barclays ups GM price target to $57 after tech day
Barclays analyst Brian Johnson raised his price target for General Motors (GM) to $57 from $55 following yesterday's tech day. The automaker closed yesterday down 72c to $43.09. While some view GM's target of commercially launching at scale autonomous ridesharing in dense urban environments in 2019 as an unrealistic target, similar to the timelines pushed by Tesla (TLSA), time with management indicated this seems possible, Johnson tells investors in a research note. GM's technology is real, and the company has a fail-safe with the autonomous vehicles to be monitored by humans at control centers, the analyst contends. The tech day reinforced Johnson's view that GM has first mover advantage in mobility. He believes the shares are due for a "multiple re-rating" and reiterates an Overweight rating on GM.
12/01/17
SBSH
12/01/17
NO CHANGE
Target $60
SBSH
Buy
Citi more confident in $134 long-term upside case for GM shares
Citi analyst Itay Michaeli says he left General Motors' investor event yesterday with greater conviction on his thesis and prior $134 long-term potential upside case for the stock. The analyst attributes yesterday's share pullback to some "sell the news" and mixed feedback from media test rides in the GM autonomous vehicles, which the analyst views as a "non-issue." He believes GM's event essentially introduced a new industry, autonomous urban networks, that's moving quickly towards commercialization. He sees the market as having a significant total addressable market of "well into hundreds of billions, or higher." Michaeli thinks GM shares "stand to re-rate meaningfully higher." He keeps a Buy rating on the stock with a $60 price target.
12/01/17
DBAB
12/01/17
NO CHANGE
Target $52
DBAB
Buy
GM shares price in very little for mobility business, says Deutsche Bank
Deutsche Bank analyst Rod Lache says that if General Motors' autonomous mobility plans come to fruition, it could have "profound implications across many Industries." Following yesterday's event, the analyst continues to believe that very little of the mobility business is reflected in GM shares. His $52 price target assumes "just" $10 for GM's autonomous mobility business. The U.S. business alone could conservatively be worth at least $20 per share, and on a global basis it could be worth $40 per share, Lache tells investors in a research note. He keeps a Buy rating on GM.
AMBA Ambarella
$62.03

7.76 (14.30%)

12/01/17
MSCO
12/01/17
NO CHANGE
Target $60
MSCO
Overweight
Ambarella commentary on computer vision 'notably stronger,' says Morgan Stanley
Morgan Stanley analyst Joseph Moore said Ambarella's commentary on its computer vision chip was notably stronger and he expects to get much more detail in the coming months, pointing to January's Consumer Electronics Show as an important upcoming catalyst. Ambarella management said they had sampled the first version of the CV chip to automotive and surveillance customers and there is a possibility they could announce auto development relationships for CV in 2018, maybe even the first half of the year, noted Moore, who maintains an Overweight rating and $60 price target on Ambarella shares.
12/01/17
ADAM
12/01/17
NO CHANGE
Target $67
ADAM
Buy
Ambarella share price undervalues computer vision IP, says Canaccord
Canaccord analyst Matthew Ramsay noted Ambarella reported solid Q3 results driven by strength in several end markets including both professional and home security, automotive, and wearable cameras. The analyst believes that although near-term bumps remain, the current share price undervalues the company's computer vision IP, growth potential, and engineering teams. Ramsay reiterated his Buy rating and raised his price target to $67 form $65 on Ambarella shares.
09/27/17
MSCO
09/27/17
NO CHANGE
Target $60
MSCO
Overweight
Morgan Stanley ups Ambarella 'bull case' to $115 on computer vision opportunity
Morgan Stanley analyst Joseph Moore said that after spending three days on a road show with Ambarella management he came away with more appreciation for the potential of the company's computer vision opportunity, where it could become a market leader. If early company claims prove accurate, he sees a "bull case" for the stock up to $115, though he cautions that even in the bull case revenue traction in ADAS will likely take multiple years. The analyst, who has a $60 base case price target on Ambarella, keeps an Overweight rating on the shares.
10/13/17
ADAM
10/13/17
NO CHANGE
Target $65
ADAM
Buy
Ambarella share price undervalues computer vision IP, says Canaccord
Canaccord analyst Matthew Ramsay noted Ambarella shares have been volatile since its last earnings report and he believes the bumps are likely to remain over the near-term. However, he believes the challenges have caused investors to undervalue its long-term computer vision hardware and software intellectual property and growth potential in more stable security and automotive markets. Ramsay reiterated his Buy rating and raised his price target to $65 from $58 on Ambarella shares.
NTNX Nutanix
$36.06

3.26 (9.94%)

12/01/17
MAXM
12/01/17
NO CHANGE
Target $51
MAXM
Buy
Nutanix price target raised to $51 from $39 at Maxim
Maxim analyst Nehal Chokshi raised his price target on Nutanix to $51 and kept his Buy rating after yesterday's earnings beat. Chokshi says the company's latest guidance removes hardware related revenue from his models, improving the sales productivity metric from 32% to 39% in FY19.
12/01/17
OPCO
12/01/17
NO CHANGE
Target $40
OPCO
Outperform
Nutanix price target raised to $40 from $34 at Oppenheimer
Oppenheimer analyst Ittai Kidron raised his price target for Nutanix to $40 saying the company last night reported another strong quarter ahead of expectations. The "clear highlight" was management's commitment to a software-focused model going forward, Kidron tells investors in a post-earnings research note. The analyst us bullish on the transition and looks forward to a "large gross margin boost over time." He maintains an Outperform rating on Nutanix.
12/01/17
PIPR
12/01/17
NO CHANGE
Target $40
PIPR
Overweight
Nutanix price target raised to $40 from $28 at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski raised his price target for Nutanix to $40 saying the company's transition to a software model highlighted its "solid" Q1 results. The transition will result in "significant" gross and operating margin expansion, and should ultimately drive a "re-rating of the multiple," Nowinski tells investors in a research note. He reiterates an Overweight rating on Nutanix.
11/29/17
BARD
11/29/17
NO CHANGE
Target $41
BARD
Outperform
Nutanix price target raised to $41 from $31 at Baird
Baird analyst Jayson Noland raised his price target on Nutanix to $41 from $31 ahead of tomorrow's Q1 report. The analyst said despite its recent share appreciation, the stock still has room to run. He sees multiple expansion as the company shifts to software-only sales. Noland reiterated his Outperform rating on Nutanix.
GCO Genesco
$25.53

-5.575 (-17.93%)

05/22/17
RILY
05/22/17
UPGRADE
Target $56
RILY
Buy
Genesco upgraded to Buy from Neutral at B. Riley
B. Riley analyst Mitch Kummetz upgraded Genesco to Buy saying Journeys is well positioned and that he's bullish on back-to-school. The analyst lowered his price target for the shares to $56 from $65.
05/25/17
RHCO
05/25/17
NO CHANGE
RHCO
Genesco weakness a buying opportunity, says SunTrust
SunTrust analyst Pamela Quintiliano would be a buyer of Genesco shares on today's weakness following the disappointng Q1 report and guidance. The analyst said trends have improved quarter-to-date with the warm weather, online growth is above expectations at both Journeys and Lids, markdowns at Journey should not be severe, and the company should begin to see the benefits in digital investments next year. Quintiliano rates Genesco a Buy with a $76 price target.
08/28/17
SUSQ
08/28/17
DOWNGRADE
SUSQ
Neutral
Genesco downgraded to Neutral from Positive at Susquehanna
05/26/17
RHCO
05/26/17
NO CHANGE
RHCO
Genesco should be bought on weakness, says SunTrust
After Genesco reported lower than expected Q1 EPS, SunTrust analyst Pamela Quintiliano notes that the company's traffic has improved in Q2. She expects the company's business to rebound further in 2H17 and recommends buying the shares on weakness.
ULTA Ulta Beauty
$212.58

-9.13 (-4.12%)

12/01/17
RBCM
12/01/17
NO CHANGE
Target $225
RBCM
Sector Perform
Ulta Beauty price target lowered to $225 from $250 at RBC Capital
RBC Capital analyst Brian Tunick lowered his price target on Ulta Beauty to $225 after yesterday's earnings, saying that while comps were in line with lowered expectations, the gross margin decline was the "sticking point" of the report amid unfavorable product shift and loyalty program promotions. Tunick keeps his Sector Perform rating, noting that although the company can maintain its EPS growth rate, the upside in the stock may be limited on slowing fundamentals of beauty product category growth.
12/01/17
WELS
12/01/17
NO CHANGE
Target $220
WELS
Market Perform
Ulta Beauty price target lowered to $220 from $242 at Wells Fargo
Wells Fargo analyst Ike Boruchow lowered his price target for Ulta Beauty to $220 saying that while the Q3 comps were "robust" once again, last night marked the second straight quarter the company did not beat its comp plan. The analyst, however, believes the larger issue is Ulta missing its gross margin plan for the third time in the past four quarters. The shares will remain "under some pressure as the market grapples with how to value this growth story which is clearly transitioning into a more stable profile," Boruchow tells investors in a post-earnings research note. He keeps a Market Perform rating on Ulta Beauty.
12/01/17
JPMS
12/01/17
NO CHANGE
Target $270
JPMS
Overweight
JPMorgan sees only 'modest pressure' for Ulta Beauty shares
JPMorgan analyst Christopher Horvers believes shares of Ulta Beauty will only see "modest pressure" today given that the company reported better than guided comps ex-hurricane in Q3 and provided an outlook for relatively improved merchandise margin performance. Further, management re-committed to 20%-plus earnings growth in 2018, Horvers tells investors in a post-earnings research note. He believes these "will likely stave off what could have been a tough day for the stock" given the 110 basis point decline in gross margin for Q3. The analyst keeps an Overweight rating on Ulta Beauty with a $270 price target. The shares in premarket trading are down 6% to $207.66.
12/01/17
MSCO
12/01/17
NO CHANGE
Target $235
MSCO
Equal Weight
Ulta Beauty price target lowered to $235 after 'mixed bag' Q3 at Morgan Stanley
Morgan Stanley analyst Simeon Gutman said Ulta Beauty offered a "mixed bag" in terms of its Q3 results, with in-line comparable sales growth but much weaker gross margins than it has had in some time. The analyst, who said competitive pressures seem to be intensifying, lowered his price target on Ulta to $235 from $245 and keeps an Equal Weight rating on the shares.
BTC Bitcoin

11/29/17
STPT
11/29/17
NO CHANGE
STPT
Standpoint raises 2018 bitcoin price target to $20,000 from $14,000
Standpoint Research analyst Ronnie Moas raised his 2018 price target for bitcoin to $20,000 from $14,000. The current price is around $10,720 and the split-adjusted price is now $12,740 when factoring in Bitcoin Cash, Bitcoin Gold and Bitcoin Diamond, Moas tells investors in an intraday email. There is "no way to justify" gold investments equaling 40 times than that of bitcoin, the analyst argues. He thinks an argument can be made that bitcoin will be equal to gold in 10-15 years. Currently, gold has $7T in investments to bitcoin's $180B, according to Moas.
11/27/17
11/27/17
DOWNGRADE
Target $30

Sell
BTIG says sell Square after 'overdone' bitcoin-fueled rally
As previously reported, BTIG analyst Mark Palmer downgraded Square (SQ) to Sell from Neutral, as he believes the stock's valuation reflects "emphatic and unimpeded growth" but fails to factor in the risks facing the company from increasing competition from First Data's (FDC) Clover, Vantiv (VNTV) and others. Other concerns, such as macroeconomic and credit-related risks, "did not go away when some investors suddenly viewed its shares as a play on a trendy cryptocurrency" following the company's confirmation that it is testing allowing users to buy and sell bitcoin using its app, Palmer tells investors. He has a $30 price target on Square shares, which closed Friday at $48.86.

TODAY'S FREE FLY STORIES

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

11:00
12/15/17
12/15
11:00
12/15/17
11:00
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark opens at $14.05,…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

EEM

MSCI Emerging Markets Index

$46.07

-0.005 (-0.01%)

11:00
12/15/17
12/15
11:00
12/15/17
11:00
Options
90K iShares Emerging Markets Fund Jun 42 puts bought for $1.04 »

90K iShares Emerging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
12/15/17
12/15
10:55
12/15/17
10:55
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

CSCO

Cisco

$37.90

-0.25 (-0.66%)

, PANW

Palo Alto Networks

$147.38

1.95 (1.34%)

10:55
12/15/17
12/15
10:55
12/15/17
10:55
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

CSCO

Cisco

$37.90

-0.25 (-0.66%)

PANW

Palo Alto Networks

$147.38

1.95 (1.34%)

SYMC

Symantec

$28.75

0.12 (0.42%)

CHKP

Check Point

$106.30

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

  • 17

    Jan

  • 26

    Feb

ACHN

Achillion

10:51
12/15/17
12/15
10:51
12/15/17
10:51
Recommendations
Achillion analyst commentary  »

Achillion CMO departure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGP

Plains GP Holdings

$21.29

0.11 (0.52%)

10:50
12/15/17
12/15
10:50
12/15/17
10:50
Options
Notable option play in Plains GP as a position adjusted »

Notable option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:46
12/15/17
12/15
10:46
12/15/17
10:46
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

FCX

Freeport McMoRan

$16.64

0.45 (2.78%)

10:45
12/15/17
12/15
10:45
12/15/17
10:45
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/15/17
12/15
10:45
12/15/17
10:45
General news
Chicago Fed's Evans voted against the rate hike »

Chicago Fed's Evans…

TEVA

Teva

$18.42

1.116 (6.45%)

10:44
12/15/17
12/15
10:44
12/15/17
10:44
Upgrade
Teva rating change  »

Credit Suisse takes Teva…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$19.49

0.26 (1.35%)

, CS

Credit Suisse

$17.59

0.065 (0.37%)

10:44
12/15/17
12/15
10:44
12/15/17
10:44
Periodicals
U.S. judge dismisses $3B suit against Deutsche, Credit Suisse, Bloomberg says »

A U.S. judge has thrown…

DB

Deutsche Bank

$19.49

0.26 (1.35%)

CS

Credit Suisse

$17.59

0.065 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACHN

Achillion

10:40
12/15/17
12/15
10:40
12/15/17
10:40
Hot Stocks
Achillion reports resignation of Chief Medical Officer »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:39
12/15/17
12/15
10:39
12/15/17
10:39
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

TEVA

Teva

$18.39

1.08 (6.24%)

10:37
12/15/17
12/15
10:37
12/15/17
10:37
Upgrade
Teva rating change  »

Teva upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXRX

Concordia

$0.86

0.3261 (61.08%)

10:37
12/15/17
12/15
10:37
12/15/17
10:37
Hot Stocks
Concordia says 'unaware' of material change to account for market activity »

Concordia International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AU

AngloGold

$9.21

0.045 (0.49%)

10:35
12/15/17
12/15
10:35
12/15/17
10:35
Options
AngloGold put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.26

-0.025 (-0.47%)

10:35
12/15/17
12/15
10:35
12/15/17
10:35
Hot Stocks
AK Steel says UAW members ratify labor agreement for Dearborn Works »

AK Steel announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:30
12/15/17
12/15
10:30
12/15/17
10:30
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

NDSN

Nordson

$143.86

16.95 (13.36%)

10:27
12/15/17
12/15
10:27
12/15/17
10:27
Recommendations
Nordson analyst commentary  »

Nordson price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:27
12/15/17
12/15
10:27
12/15/17
10:27
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

10:25
12/15/17
12/15
10:25
12/15/17
10:25
General news
Treasury Action: Treasuries will remain in a bear-bull tug-o-war into 2018 »

Treasury Action:…

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
JPMorgan household/personal product analyst has analyst/industry conference call »

Beverages, Household…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

, FOXA

21st Century Fox

$34.88

2.13 (6.50%)

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Cable, Media &…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

DIS

Disney

$110.93

0.36 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
JPMorgan insurance analyst has analyst/industry conference call »

Property & Casualty…

TEVA

Teva

$18.21

0.91 (5.26%)

10:24
12/15/17
12/15
10:24
12/15/17
10:24
Upgrade
Teva rating change  »

Teva upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.